Catasys provides an integrated behavioral health program called OnTrak that identifies high-cost individuals with behavioral health issues and engages them in a 52-week treatment program. Catasys uses predictive analytics to identify eligible members from claims data provided by health plans. OnTrak reduces medical costs by about 50% and provides a 3-to-1 return on investment for health plans. Catasys expects $20 million in billings in 2018 based solely on its existing pool of eligible members.
Understand what consumers value most when managing their health and how much additional responsibility they’re willing to take on to reduce the cost of their healthcare.
Behavioral Health Industry Insights - 2016Duff & Phelps
This issue of Behavioral Health Insights details the impact of deinstitutionalization and the IMD Exclusion on the behavioral healthcare landscape. On April 25, 2016, the CMS issued a long-awaited official rule meaningfully changing the IMD Exclusion provisions in response to access concerns over inpatient psychiatric and substance use disorder services
Will New Healthcare Policy Impact Value-Based Healthcare?Health Catalyst
The final days of 2016 were fraught with uncertainty about what Congress and the new Trump Administration would do to the Affordable Care Act (ACA) and the healthcare regulatory landscape overall. So far, in 2017, we do not have much more clarity. Repeal, repeal and replace, repeal and delay, modify without repeal—there are now even more questions than answers and still no consensus Republican plan in sight. Yet healthcare executives would certainly appreciate some modicum of clarity, at least on the narrower topic of whether the shift to value-based healthcare models will continue under whatever new system is coming. This webinar attempts to add clarity by analyzing what we know so far, as reflected in the limited actual evidence that is available.
Join Dan Orenstein, General Counsel, Health Catalyst, as he analyzes these three key pieces of information:
The 21st Century Cures Act (Cures)
The Executive Order on reducing the “burden” of the Affordable Care Act (ACA)
Tom Price’s comments at his confirmation hearings
Understand what consumers value most when managing their health and how much additional responsibility they’re willing to take on to reduce the cost of their healthcare.
Behavioral Health Industry Insights - 2016Duff & Phelps
This issue of Behavioral Health Insights details the impact of deinstitutionalization and the IMD Exclusion on the behavioral healthcare landscape. On April 25, 2016, the CMS issued a long-awaited official rule meaningfully changing the IMD Exclusion provisions in response to access concerns over inpatient psychiatric and substance use disorder services
Will New Healthcare Policy Impact Value-Based Healthcare?Health Catalyst
The final days of 2016 were fraught with uncertainty about what Congress and the new Trump Administration would do to the Affordable Care Act (ACA) and the healthcare regulatory landscape overall. So far, in 2017, we do not have much more clarity. Repeal, repeal and replace, repeal and delay, modify without repeal—there are now even more questions than answers and still no consensus Republican plan in sight. Yet healthcare executives would certainly appreciate some modicum of clarity, at least on the narrower topic of whether the shift to value-based healthcare models will continue under whatever new system is coming. This webinar attempts to add clarity by analyzing what we know so far, as reflected in the limited actual evidence that is available.
Join Dan Orenstein, General Counsel, Health Catalyst, as he analyzes these three key pieces of information:
The 21st Century Cures Act (Cures)
The Executive Order on reducing the “burden” of the Affordable Care Act (ACA)
Tom Price’s comments at his confirmation hearings
Catasys, Inc. harnesses proprietary big data predictive analytics, artificial intelligence and telehealth, combined with human intervention, to deliver improved member health and cost savings to health plans through integrated technology enabled treatment solutions. It is our mission to provide access to affordable and effective care, thereby improving health and reducing cost of care for people who suffer from the medical consequences of behavioral health conditions; helping these people and their families achieve and maintain better lives
Data-Based Planning for Effective Prevention
State Epidemiological Outcomes Workgroups
Presents the key principles and core expectations of the State Epidemiological Outcomes Workgroups, designed to use data to inform and enhance state and community decisions regarding substance abuse and mental health disorder prevention programs.
What do big data and advanced analytics mean for healthcare? This question was answered during the Georgia Society of CPAs (GSCPA) 2015 Healthcare Conference, February 6, at the Cobb Galleria Centre in Atlanta, GA. PYA Principal Marty Brown and PYA Analytics President & CEO Brian Worley presented “Big Data Applications in Healthcare.”
Big Data: Implications of Data Mining for Employed Physician Compliance Manag...PYA, P.C.
PYA Principal Denise Hall, along with King & Spalding’s Michael Paulhus, co-presented “Big Data: Implications of Data Mining for Employed Physician Compliance Management” at the Health Care Compliance Association’s (HCCA) 19th Annual Compliance Institute.
A consumer study prepared by PwC to investigate how behavioral, regulatory, and technological disruption are changing consumer's approaches to managing their health.
Director Rodriguez provides an overview to the new impact of the Omnibus HIPAA Rulemaking and highlights OCR’s commitment to enforcement, audit and education initiatives in the coming year.
Fair Market Value: What Rural Providers Need to Know PYA, P.C.
PYA Principal Tynan Olechny and Senior Manager Annapoorani Bhat provided important information for rural providers related to fair market value and commercial reasonableness considerations during a National Rural Health Association webinar, “Valuations: What Rural Providers Need to Know."
Modern Physician-Hospital Affiliations in an Era of Increased Fraud and Abuse...PYA, P.C.
PYA Senior Manager Chris Beckham co-presented “Modern Physician-Hospital Affiliations in an Era of Increased Fraud and Abuse Scrutiny” with Ross Burris of Polsinelli at the American Health Lawyer Association’s (AHLA) Physicians and Hospitals Law Institute, February 8-10, 2016.
How to Engage Physicians in Best Practices to Respond to Healthcare Transform...PYA, P.C.
PYA Principal Kent Bottles, MD, spoke about physician engagement when it comes to value payment models during “How to Engage Physicians in Best Practices to Respond to Healthcare Transformation” at the Georgia Society of Certified Public Accountants’ (GSCPA) 2016 Healthcare Conference, February 11, 2016. Dr. Bottles discussed the difficulty of weaning physicians from fee-for-service payment models and the often-unappreciated reasoning behind the shift to value-based payment models. He also highlighted MACRA, MIPS, patient satisfaction surveys, Physician Compare, and the ProPublica Surgeon Scorecard.
The FDA and industry: A recipe for collaborating in the New Health EconomyPwC
Pharmaceutical and life science companies and their chief regulator – the FDA – must find new ways to collaborate to meet 21st century demands.
Web Page: http://www.pwc.com/us/en/health-industries/health-research-institute/hri-pharma-life-sciences-fda.jhtml
ACOs and CINs — Where Did They Start, How Have They Evolved, and Where Are Th...Health Catalyst
As the types and structures of Accountable Care Organizations (ACOs) and Clinically Integrated Networks (CINs) continue to evolve, organizations moving into value-based care face an ever-changing landscape. Alternative payment model arrangements have driven provider organizations to hone in on specific tactics to meet their contractual and strategic objectives.
Please join Health Catalyst Senior Vice President Dr. Amy Flaster and Population Health Management Consultant Jonas Varnum as they discuss the evolution of the ACO and CIN models, what new tools ACOs employ today to promote success, and lessons learned from organizations that have succeeded in alternative payment models. They will dive deep into lessons learned in addition to providing a primer on what has always been and continues to be vitally important to success in value based care. Specifics they will cover include:
- Approaches to simplify quality metric reporting
- Enhanced methodology that zeroes in on identifying high-value opportunities to improve patient populations
- Key tips to expand your business with new contracts
Dr. Flaster and Mr. Varnum’s combined experience make them uniquely qualified to guide you in your ACO or CIN journey. Dr. Flaster comes from a clinical background where she worked as Associate Medical Director at Partners HealthCare - one of the largest ACOs in the country. Mr. Varnum is a professional services strategy leader with demonstrated expertise delivering payment model transformation and helping providers and payers to strategically adjust their operations.
Big Data: Implications of Data Mining for Employed Physician Compliance Manag...PYA, P.C.
PYA Principal Denise Hall presented “Big Data: Implications of Data Mining for Employed Physician Compliance Management” at Becker’s Annual CEO & CIO Strategy Roundtables, November 18-19, 2015.
The presentation explored:
Data being aggregated by the government, as well as new approaches by regulators.
Public relations and litigation risk from the public dissemination of data by the government.
Big data connections to payment through quality metrics and the potential for new theories of False Claims Act (FCA) suits.
Internal use of broad spectrum analytics in employed physician compliance management.
Determination of risk tolerance and the customization of “outside the box” analytics.
Benchmarking, monitoring, and defining physician-focused risk area reviews.
Big Data: Implications of Data Mining for Employed Physician Compliance Manag...PYA, P.C.
PYA Consulting Manager Kristen Lilly presented “Big Data: Implications of Data Mining for Employed Physician Compliance Management” during a webinar for the Georgia chapter of the Healthcare Financial Management Association (Georgia HFMA), March 31, 2016.
The presentation explored:
Public relations and litigation risk from the public dissemination of data by the government.
Internal use of broad spectrum analytics in employed physician compliance management.
Determination of risk tolerance and the customization of “outside the box” analytics.
Benchmarking, monitoring, and defining physician-focused risk area reviews.
As healthcare is a language “all its own,” PYA Principal David McMillan presented “Learning the New Language of Healthcare" at the Georgia Society of CPAs' 2014 Healthcare Conference.
Exclusive Contracting and Incentivizing Quality in Your Hospitalist ProgramPYA, P.C.
PYA Principal Carol Carden co-presented a session along with Mark Easterly, Vice President of Legal Services for Houston Methodist, on “Exclusive Contracting and Incentivizing Quality in Your Hospitalist Program" at the AHLA Physicians and Hospitals Law Institute.
Catasys, Inc. harnesses proprietary big data predictive analytics, artificial intelligence and telehealth, combined with human intervention, to deliver improved member health and cost savings to health plans through integrated technology enabled treatment solutions. It is our mission to provide access to affordable and effective care, thereby improving health and reducing cost of care for people who suffer from the medical consequences of behavioral health conditions; helping these people and their families achieve and maintain better lives
Data-Based Planning for Effective Prevention
State Epidemiological Outcomes Workgroups
Presents the key principles and core expectations of the State Epidemiological Outcomes Workgroups, designed to use data to inform and enhance state and community decisions regarding substance abuse and mental health disorder prevention programs.
What do big data and advanced analytics mean for healthcare? This question was answered during the Georgia Society of CPAs (GSCPA) 2015 Healthcare Conference, February 6, at the Cobb Galleria Centre in Atlanta, GA. PYA Principal Marty Brown and PYA Analytics President & CEO Brian Worley presented “Big Data Applications in Healthcare.”
Big Data: Implications of Data Mining for Employed Physician Compliance Manag...PYA, P.C.
PYA Principal Denise Hall, along with King & Spalding’s Michael Paulhus, co-presented “Big Data: Implications of Data Mining for Employed Physician Compliance Management” at the Health Care Compliance Association’s (HCCA) 19th Annual Compliance Institute.
A consumer study prepared by PwC to investigate how behavioral, regulatory, and technological disruption are changing consumer's approaches to managing their health.
Director Rodriguez provides an overview to the new impact of the Omnibus HIPAA Rulemaking and highlights OCR’s commitment to enforcement, audit and education initiatives in the coming year.
Fair Market Value: What Rural Providers Need to Know PYA, P.C.
PYA Principal Tynan Olechny and Senior Manager Annapoorani Bhat provided important information for rural providers related to fair market value and commercial reasonableness considerations during a National Rural Health Association webinar, “Valuations: What Rural Providers Need to Know."
Modern Physician-Hospital Affiliations in an Era of Increased Fraud and Abuse...PYA, P.C.
PYA Senior Manager Chris Beckham co-presented “Modern Physician-Hospital Affiliations in an Era of Increased Fraud and Abuse Scrutiny” with Ross Burris of Polsinelli at the American Health Lawyer Association’s (AHLA) Physicians and Hospitals Law Institute, February 8-10, 2016.
How to Engage Physicians in Best Practices to Respond to Healthcare Transform...PYA, P.C.
PYA Principal Kent Bottles, MD, spoke about physician engagement when it comes to value payment models during “How to Engage Physicians in Best Practices to Respond to Healthcare Transformation” at the Georgia Society of Certified Public Accountants’ (GSCPA) 2016 Healthcare Conference, February 11, 2016. Dr. Bottles discussed the difficulty of weaning physicians from fee-for-service payment models and the often-unappreciated reasoning behind the shift to value-based payment models. He also highlighted MACRA, MIPS, patient satisfaction surveys, Physician Compare, and the ProPublica Surgeon Scorecard.
The FDA and industry: A recipe for collaborating in the New Health EconomyPwC
Pharmaceutical and life science companies and their chief regulator – the FDA – must find new ways to collaborate to meet 21st century demands.
Web Page: http://www.pwc.com/us/en/health-industries/health-research-institute/hri-pharma-life-sciences-fda.jhtml
ACOs and CINs — Where Did They Start, How Have They Evolved, and Where Are Th...Health Catalyst
As the types and structures of Accountable Care Organizations (ACOs) and Clinically Integrated Networks (CINs) continue to evolve, organizations moving into value-based care face an ever-changing landscape. Alternative payment model arrangements have driven provider organizations to hone in on specific tactics to meet their contractual and strategic objectives.
Please join Health Catalyst Senior Vice President Dr. Amy Flaster and Population Health Management Consultant Jonas Varnum as they discuss the evolution of the ACO and CIN models, what new tools ACOs employ today to promote success, and lessons learned from organizations that have succeeded in alternative payment models. They will dive deep into lessons learned in addition to providing a primer on what has always been and continues to be vitally important to success in value based care. Specifics they will cover include:
- Approaches to simplify quality metric reporting
- Enhanced methodology that zeroes in on identifying high-value opportunities to improve patient populations
- Key tips to expand your business with new contracts
Dr. Flaster and Mr. Varnum’s combined experience make them uniquely qualified to guide you in your ACO or CIN journey. Dr. Flaster comes from a clinical background where she worked as Associate Medical Director at Partners HealthCare - one of the largest ACOs in the country. Mr. Varnum is a professional services strategy leader with demonstrated expertise delivering payment model transformation and helping providers and payers to strategically adjust their operations.
Big Data: Implications of Data Mining for Employed Physician Compliance Manag...PYA, P.C.
PYA Principal Denise Hall presented “Big Data: Implications of Data Mining for Employed Physician Compliance Management” at Becker’s Annual CEO & CIO Strategy Roundtables, November 18-19, 2015.
The presentation explored:
Data being aggregated by the government, as well as new approaches by regulators.
Public relations and litigation risk from the public dissemination of data by the government.
Big data connections to payment through quality metrics and the potential for new theories of False Claims Act (FCA) suits.
Internal use of broad spectrum analytics in employed physician compliance management.
Determination of risk tolerance and the customization of “outside the box” analytics.
Benchmarking, monitoring, and defining physician-focused risk area reviews.
Big Data: Implications of Data Mining for Employed Physician Compliance Manag...PYA, P.C.
PYA Consulting Manager Kristen Lilly presented “Big Data: Implications of Data Mining for Employed Physician Compliance Management” during a webinar for the Georgia chapter of the Healthcare Financial Management Association (Georgia HFMA), March 31, 2016.
The presentation explored:
Public relations and litigation risk from the public dissemination of data by the government.
Internal use of broad spectrum analytics in employed physician compliance management.
Determination of risk tolerance and the customization of “outside the box” analytics.
Benchmarking, monitoring, and defining physician-focused risk area reviews.
As healthcare is a language “all its own,” PYA Principal David McMillan presented “Learning the New Language of Healthcare" at the Georgia Society of CPAs' 2014 Healthcare Conference.
Exclusive Contracting and Incentivizing Quality in Your Hospitalist ProgramPYA, P.C.
PYA Principal Carol Carden co-presented a session along with Mark Easterly, Vice President of Legal Services for Houston Methodist, on “Exclusive Contracting and Incentivizing Quality in Your Hospitalist Program" at the AHLA Physicians and Hospitals Law Institute.
mHealth Israel_US Health Insurance Overview- An Insider's PerspectiveLevi Shapiro
Presentation about the US Health Insurance Sector by Lori Rund, VP, Product Management and Market Intelligence at Health Alliance Plan, a managed care organization owned by the Henry Ford Health System, with 650,000 lives. Lori is responsible for the identification, concept building, researching and business case developments for new products, services and markets. She develops and leads comprehensive market intelligence functions to help the organization better understand industry trends and identify business opportunities.
Prior to joining Health Alliance Plan, Lori was Director of Product Development and Market Intelligence at Health Alliance Medical Plans in Illinois and Director of Market Research and Strategy at Carle Clinic Association, also in Illinois.
Investments in Behavioral Health: Drivers and Outlook - Behavioral Health Cra...Epstein Becker Green
Webinar by attorney Purvi Maniar of Epstein Becker Green - April 5, 2016. Part of the Behavioral Health Crash Course Webinar Series.
This webinar will provide:
* A discussion of the main drivers of growth in investment in behavioral health, including the focus on population health management and mental health parity laws
* The outlook for providers of behavioral health services, including an overview of areas of legal focus and potential competition
http://www.ebglaw.com/events/investme...
These materials have been provided for informational purposes only and are not intended and should not be construed to constitute legal advice. The content of these materials is copyrighted to Epstein Becker & Green, P.C. ATTORNEY ADVERTISING.
mHealth Israel_GEARING COMMUNICATIONS TO RAISE CAPITAL AND ATTRACT CUSTOMERS_...Levi Shapiro
Presentation by Gil Bashe, Managing Director, Healthcare Practice, Finn Partners: "GEARING COMMUNICATIONS TO RAISE CAPITAL AND ATTRACT CUSTOMERS- FROM PLAN TO PARTNERS TO PATIENTS". Includes tips to avoid failure by embracing complexity, description of the Health Ecosystem Landscape, developing a plan to impact care, cost and outcomes, overview of the US Payer market, and top digital health influencers.
An Industry Collaboration's Perspectives on the Value of Patient Support Prog...TransCelerate
The Value of Safety Information Data Sources Initiative will seek to identify sources of safety information for a single high value valid cases and develop a proposed method for aggregate reporting of lower value cases.
The Future of Personalizing Care Management & the Patient ExperienceRaphael Louis Vitón
Actionable segmentation model findings - by Raphael Louis Vitón & Dream team of industry experts, physicians and leaders from Blue Cross, GEHealthCare, RingLeaderVentures, Maddock Douglas, Dr.Daniel Friedland, etc working on improving health outcomes by Personalizing the Care Management business model for Better Outcomes & Better Economics (through patient empowerment)
How a Revamped Data Analytics Approach Can Mitigate Healthcare Disparities.pdfaNumak & Company
The healthcare industry has learned an unwelcome lesson because of the COVID-19 outbreak.
In addition to putting a significant load on the healthcare system, it has helped us understand
how crucial it is to update data to lessen healthcare inequity. Therefore, selecting the ideal
healthcare analytics consulting partner is essential if we want to advance long-term equity in
healthcare and eliminate bias from the data.
Extended Real-World Data: The Life Science Industry’s Number One AssetHealth Catalyst
The life science industry has historically relied on sanitized clinical trials and commoditized data sources (largely claims) to inform its drug development process—an under-substantiated approach that didn’t reflect how a new drug would affect broader patient populations. In an effort to gain more accurate insight into the patient experience and bring drugs to market more efficiently and safely, the industry is now expanding into extended real-world data (RWD).
To access the needed breadth and depth of patient-centric data, life science companies must partner with a healthcare transformation company that has three key qualities:
A broad and deep data asset.
Extensive provider partnerships.
An outcomes-improvement engine to support the next generation of drug development.
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
Dócola is a social good organization with the only free care communication platform that consolidates thousands of free and low-cost patient education resources from the leading nonprofit, government, and commercial organizations in one marketplace. Plus, you can easily create and upload your own resources.
INNO HOLDINGS INC. is an innovative building-technology company with a mission to transform the construction industry with our proprietary cold-formed steel- framing technology and other building innovations
Everything Blockchain builds platforms of trust for the modern enterprise and is on a mission to ensure every organization has access to the tools and platforms that enable them to manage, store, and protect data without the cost and complexity that holds them back today. The Company’s patented advances in engineering deliver the essential elements needed for real-world business use: speed, security, and efficiency. Everything Blockchain’s current business lines include: EB Advise, Build DB and EB Control.
ASP Isotope is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries.
MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. It’s our mission to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.
Digital Ally, Inc. is a diversified holding company with operations in video solution technology, human and animal health protection products, healthcare revenue cycle management, ticket brokering and marketing, and event production. The Company pursues an acquisition strategy that targets organizations with positive earnings, strong growth potential, innovation, and operational synergies. To maximize long-term shareholder value, Digital Ally intends to spin-off its ticketing and entertainment business lines into a separate public company in 2023. The spin-off will create two optimized, tech-driven public companies with strong growth opportunities and operating metrics.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
Aditxt is a global innovation company focused on discovering and developing precision medicine innovations and deploying them into high-performing businesses. Aditxt’s diverse innovation portfolio includes: Adimune™, Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir™, Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta™, Inc., offering convenient, rapid, personalized, and high-quality lab testing —anytime and anywhere at its CLIA certified and CAP accredited clinical laboratory based in Richmond, VA.
1847 Holdings LLC, a publicly traded diversified acquisition holding company, was founded by Ellery W. Roberts, a former partner of Parallel Investment Partners, Saunders Karp & Megrue and Principal of Lazard Freres Strategic Realty Investors. EFSH's investment thesis is that capital market inefficiencies have left the founders and/or stakeholders of many small business enterprises and lower-middle market businesses with limited exit options, despite the intrinsic value of their business. Given this dynamic, EFSH can consistently acquire "solid" businesses for reasonable multiples of cash flow and then deploy resources to strengthen the infrastructure and systems to improve operations. These improvements may lead to a sale or IPO of an operating subsidiary at considerably higher valuations than the purchase price (as successfully demonstrated with the mid-2020 IPO of 1847 Goedeker on the NYSE American) and/or alternatively, an operating subsidiary may be held in perpetuity and contribute to EFSH's ability to pay regular and special dividends to shareholders.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
SPI Energy is a global renewable energy company and provider of solar storage and electric vehicle (EV) solutions that was founded in 2006 in Roseville, California and is headquartered in McClellan Park, California. The Company has three core divisions: SolarJuice which has solar wholesale distribution, as well as residential solar and roofing installation and solar module manufacturing (Solar4America & SEM Wafertech), SPI Solar and Orange Power which operates a commercial & utility solar division, and the EdisonFuture/Phoenix Motor EV division. SolarJuice is the leader in renewable energy system solutions for residential and small commercial markets and has extensive operations in the Asia Pacific and North America markets. The SPI Solar commercial & utility solar division provides a full spectrum of EPC services to third party project developers, and develops, owns and operates solar projects that sell electricity to the grid in multiple regions, including the U.S., U.K., and Europe. Phoenix Motor is a leader in medium-duty commercial electric vehicles, and is developing EV charger solutions, electric pickup trucks, electric forklifts, and other EV products. SPI maintains global operations in North America, Australia, Asia and Europe and is also targeting strategic investment opportunities in fast growing green energy industries such as battery storage, charging stations, and other EVs which leverage the Company's expertise and substantial solar cash flow.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
2. Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor
provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve
a variety of risks and uncertainties, many of which are beyond our control, which may cause actual results to differ materially from stated
expectations. These risk factors include, among others, changes in regulations or issuance of new regulations or interpretations, limited
operating history, our inability to execute our business plan, increase our revenue and achieve profitability, lower than anticipated eligible
members under our contracts, our inability to recognize revenue, lack of outcomes and statistically significant formal research studies,
difficulty enrolling new members and maintaining existing members in our programs, the risk that the treatment programs might not be
effective, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the
health care industry, the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern, our
ability to raise additional capital when needed and our liquidity. You are urged to consider statements that include the words “may,” “will,”
“could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plan,” “anticipates,” “intends,” “continues,” “forecast,”
“designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and
description of the risks and uncertainties we face, please refer to our most recent Securities and Exchange Commission filings which are
available on its website at http://www.sec.gov. Such forward-looking statements, whether as a result of new information, future events or
otherwise, except as required by law.
2
Forward-Looking Statements
3. Catasys combines Big Data analytics and predictive modeling with state-of-the-art
treatment programs for Behavioral Health diseases
! Focuses on “treatment avoidant” member population
! Virtual, scalable, replicable, data supported, evidenced based practices
! Enhances members’ access to care
! Provides for full reimbursement
At a Glance
Ticker NASDAQ: CATS
Stock Price* $3.75
Common Shares
Outstanding
15,889,171
Float $4.7M
Average Daily
Volume
56,000
Market Cap $59.6M
Warrants (WAEP
$4.88)
1,921,528
Analyst Coverage
Chardan Capital;
Joseph Gunnar;
Tailwinds
Research Group
Solving Today’s Challenge of Behavioral Health Care
3
The Health Care Problem
Underserved populations with behavioral health conditions (substance use
disorder, depression, anxiety) do not seek treatment (avoidant population)
! Access to care
! Reimbursement
! In companion with other chronic diseases, behavioral health conditions
increase health care costs at a significant multiple of norms
The Catasys Solution
* At December 29, 2017
4. Investment Thesis
4
! Catasys’ solution (OnTrak) reduces medical costs by ~50%
for enrolled members
! Incentivizes health plans to pay 100% of member treatment costs
! Provides health plans a 3-to-1 ROI
! OnTrak program targets individuals suffering from chronic
disorders such as substance use disorder, anxiety and
depression who rarely seek care
! Large market opportunity with no direct competitors
! Financial Guidance of $20 Million for 2018
! Based solely on existing outreach pool of individuals (25,000), with
newly signed agreements and higher enrollments from existing
agreements adding incremental growth potential
! Guidance does not include any upside potential from new contracts,
subsequent launches from existing contracts, and expansions within
existing contracts, which would all be incrementally beneficial.
Signed Contracts with
Tier-1 Health Insurance Companies
! Average receivables of 45 days upon billing
! Currently enrolling participants in 19 states
! Significant embedded revenue growth as
current agreements ramp and expand
Billings*
2018E $20M
Exit Run Rate at End of 2018E $25M
* Billings: Catasys contracts are generally designed to provide cash fees on a monthly basis based on enrolled members. To the extent contracts may include a minimum
performance guarantee; Catasys reserves a portion of the monthly fees that may be at risk until the performance measurement period is completed. A Non-GAAP
reconciliation is available at the end of this presentation.
5. 2004
Catasys is founded
with the goal of
improving the
options for those
with behavioral
health needs
2010
First OnTrak
contract is
signed
2015
Catasys completes
one-year study with
Humana.
After favorable
results, signs
National Agreement
2016
Catasys expands
rollout of OnTrak
program in 18
states
2017
Catasys
expands
rollout of
OnTrak
program to 19
states
Outreach pool
of individuals
exceeds
25,000, a
record for the
Company
5
The Catasys Solution – Entering Growth Phase
2018
Catasys’ OnTrak solution
has gained traction, is
increasing enrollment
significantly, and the
largest health care
plans are signed and
supporting the program.
Based solely on existing
outreach pool, Catasys
expects to report
billings of $20M for 2018
7. 7
! Members with behavioral health disorders average higher medical costs for covering health insurance
providers
! Treatment costs of approximately $201 billion for behavioral health (2013)
! Compared to $147 billion for cardiovascular conditions and $122 billion for oncology
Behavioral Health Disorders
27 million people suffer from
substance use disorder
43 million U.S. Adults have
an anxiety disorder
15.6 million people
suffer from depression
Only 2 of 10 seek treatmentOnly 1 of 3 seek treatmentOnly 1 of 10 seek treatment
Source: National Survey on Drug Use and Health, September 4, 2014: Substance Use and Mental Health Estimates from the 2013 National Survey on Drug Use and Health: Overview of Findings
National Institute of Mental Health (NIMH): Any Anxiety Disorder Among Adults - https://www.nimh.nih.gov/health/statistics/prevalence/any-anxiety-disorder-among-adults.shtml, January 2016.
National Institute of Mental Health (NIMH): Major Depression Among Adults - http://www.nimh.nih.gov/health/statistics/prevalence/major-depression-among-adults.shtml , January 2016.
U.S. Department of Health and Human Services Substance Abuse and Mental Health Services Administration Study on Behavioral Health Spending & Use Accounts 1986 – 2014, printed 2016 - http://store.samhsa.gov/shin/content/SMA16-4975/SMA16-4975.pdf. Source: Health Affairs
8. 8
Behavioral Health Disorders – Eligible Members Cost up to 4.5X
!"
!#$"""
!%$"""
!&$"""
!'$"""
!($"""
!)$"""
!*$"""
+,-./0.12341 520678 93-4:8/ ;6/413<=>831 ?38@.0.2 ;5? ;A>? ;+B
5::=A06./ ;8082,2=C:3D3@:.
E='#*F
E=''GF E=#H)F
E=&#%F
E&*#F
E=%"&F
E=#)%F
E=#&"F
PerMemberPerMonth
9. 9
Catasys Eligible Populations
Catasys’ eligible population makes up 22% of the $1.1 trillion private healthcare costs in the U.S.
Eligible population costs health plans $30,000 on average per member per year
! Catasys provides the health plan ~50% savings per enrolled member
! Provide a 3-to-1 R-O-I
! 20% target for eligible enrollees
! Incentivizing health plans to cover 100% of the cost to treat each patient
Catasys customers include commercial, Medicare and Medicaid plans. Based on the Company’s data, the member
populations have a different incidence of the targeted behavioral health disorders.
! Commercial population:
! Substance Use Disorder (SUD) members - approximately 0.45% of the adult members eligible
! SUD, Depression (Dx) and Anxiety (Ax) - approximately 2.00% of the adult members eligible
! Medicare Advantage & Medicaid population:
! SUD members - approximately 1.13% of the adult members eligible
! SUD, Dx and Ax - approximately 2.67% of the adult members eligible
Source: Catasys’ data and analytics derived from actual health plan claims data
10. ! Majority of high cost members with coexisting behavioral and medical conditions do not seek treatment
(passive)
! Small percentage of members enroll in outpatient and an even smaller percentage enroll in inpatient
treatment centers (facility based)
! Not cost effective – the expense puts it out of reach of most patients
! Short-term care – Research indicates the 30-day program is less likely to succeed compared to a longer
program given the duration of care
! No data – A lack of data on impact on patients’ health and ongoing costs to health plans
! Lack of evidence based best practices
! Little to no integration with medical and psychosocial treatment
! Time prohibitive – avg. person unable to leave work for a month or more
! Low reimbursement – health plans do not offer high reimbursements for inpatient treatment centers due to
high costs and lack of data to prove impact on patient health
10
Source: National Institute on Drug Abuse - Principles of Drug Addition Treatment: A Research-Based Guide - https://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition/principles-effective-treatment
Industry Challenges that Catasys Addresses
12. 12
OnTrakTM : Proprietary Integrated Approach
The OnTrak solution is a fully integrated approach that includes:
! Predictive analytics used to identify and understand the eligible members to engage
! Ongoing outreach, engagement and modification of behavior techniques
! 52 week outpatient program
! Member centric – patients receive a customized treatment based on their needs
! Care Coach support
! Integrated medical and psychosocial treatment
! Member electronic clinical record
! Provider training and ongoing evaluations
! Development of select provider networks
! High intensity
13. 13
Steps to the Process
Source: Catasys data and analysis
! Catasys identifies, enrolls, engages and treats hidden, passive, care avoidant, high cost members
1. Partnering: Catasys has been engaged by several of the leading health plan providers in the U.S.
2. Data ingest: each health plan provides Catasys with member data on a regular basis
3. Identifying Eligible Participants: through proprietary analytics and predictive modeling, Catasys
identifies the right members driving current/future medical spend
4. Engages: using unique, sustained outreach and enrollment tactics, Catasys places members directly
into OnTrak
5. Treats: Catasys provides evidence based, 52 week outpatient treatment program, OnTrak
14. 14
OnTrakTM : Identifying the Right Patients
Using BIG DATA, knowing who to engage…
! Receive medical claims data from contracted health insurance companies
! Catasys uses predictive analytics and models to identify which members have
coexisting behavioral and medical conditions:
! Solution initially focused on SUD, anxiety and depression
! Eligible members average $30,000 annual claims expense
! Data mining techniques and analytics are used to identify which members are
likely to have significant impactable costs
! 73% of Catasys identified members do not have any behavioral health treatment
claims in the last year – clear need for appropriate care
Source: Catasys data and analysis
15. ! Care avoidant members struggling with behavioral health disorders are typically difficult to engage
! Catasys’ outreach program successfully convinces high cost, care avoidant members to enroll in the
OnTrak program
! Outreach tactics:
15
OnTrakTM : Outreach and Enrollment
Source: Catasys data and analysis
1. Use multiple modalities for outreach, such as phone and mail outreach
2. Use motivating communication that is patient research driven
! Utilize direct knowledge of trigger points
! Research to understand behaviors, motivators and fears
3. Build relationship and establish trust with Care Coach
! Consistency of Care Coach or outreach specialist serves as point of contact over the
outreach campaign, to facilitate comfort with enrollment
16. 16
52 Weeks
Medical & Pharmacological
16
52 Weeks
Medical & PharmacologicalMedical & PharmacologicalMedical & Pharmacological
Psychosocial Treatments
Community Based Programs
Medical & Pharmacological
(as appropriate)
! Medical evaluation and assessment
! Pharmacological intervention
! MD involvement
Psychosocial
! Proprietary OnTrak manualized psychosocial
treatment program
! Developed in coordination with leading experts in
SUD, anxiety and depression
! Focused on Cognitive Behavioral and Motivational
Enhancement Therapy
Care Coaching
! Personal Care Coach
! 52 weeks continuous support and coaching
! Helps assess, manage and support members’
recovery
Care Coaching
- Outreach
- Enrollment
- Engagement
- Retention
OnTrakTM : A Fully Immersive 52-week Program
17. 17
OnTrakTM : Humana and Catasys Joint Evaluation
Source: Catasys data and analysis
! In April 2015, Humana and Catasys reported the results of a retrospective evaluation of the
effectiveness of the OnTrak program in a poster at the American Society of Addiction Medicine
! OBJECTIVE:
! Compare changes in ER visits and inpatient
hospitalizations for participants in the substance abuse
treatment (SAT) group
! Compare changes in total cost of care among participants
in SAT group versus eligible individuals who did not
participate (control)
! RESULTS:
! 16% fewer ER visits
! 67% fewer inpatient hospitalizations
! 46% reduction in health care costs compared to a 14%
increase in costs for the control group
19. 19
Defining Catasys’ Market Opportunity
(1) Source: Kaiser Family Foundation / US GOV
The Catasys
Opportunity
TOTAL ELIGIBLE LIVES:
3,773,048
Catasys Enrollment Rate: 20%
Medicare
Advantage
3%, or 519,000
Managed Medicaid
4%, or 750,000
Commercial
2%, or 2,524,048
Of the 161.8M of Insurable Adults, below are those afflicted
with substance use disorder, anxiety, and depression
Total Insured
Market
Medicare
Advantage
17.3M
Managed
Medicaid
36.5M
Commercial
151.4M
Adults Approximate Market Size:
161.8 Million
Adults
17,300,000
100%
Adults
18,250,000
50%
Adults
126.2 Million
84%
20. Scaling the business rapidly converts into Revenue / Cash Flow
!"
Revenue per patient enrolled $8,500
Revenue per enrolled member at 78% retention $6,630
Revenue per 10,000 enrolled members $66,300,000
(1) All amounts are estimates and are calculated on adult lives (age 18+). Retention rates reflect the number of members who remain eligible for the program that stay enrolled; assumes per enrolled member monthly fee structure, while other fee
structures will vary.
Source: Ingenix Consulting database, 20MM commercial plan lives 2005-2006 and Catasys Analysis.
Revenue Model
Total Lives Covered
(Current Catasys Clients)
23.1 Million Members
70 Million Members
13 Million Members
21. ! Typically 3-year agreements with health plans
! Catasys collects its fee based on either an initial payment, over the course of the first
three months of enrollment, or on a monthly basis
! Receivables average 45 days
! Catasys stops charging if patient withdraws from program
!#
Economics of the OnTrak Program
Breakout of Services Provided
Cost of physicians for initial 4 weeks
Cost of psychologist for the first 12 visits
Care Coaches
Other Associated Costs
22. ! Costs are highly scalable as each incremental dollar in revenue does not require an equal expense
as enrollment increases
! Outreach – each person can handle 1,500 potential patients
! Care Coaches – each person can handle 60 people
! Only variability where revenue dollars do not drop are in the initial launch of a plan
! Over $225 million in Federal NOL that it expects to utilize against future net income
!!
Operating Costs / Scalability + Well Capitalized for Growth
Completed Capital Raise and Uplisting in April 2017
Capital being used to support expected growth
Cash
(Post Offering)
$10.3 million
Long-Term Debt $0
23. $20
$25
$0
$5
$10
$15
$20
$25
$30
2018 E Run Rate at End of 2018
23
(in millions)
Source: Catasys management’s projections for 2018
Billings Projections
Upside Drivers For Guidance
! New Contracts
! Subsequent Launches from Existing
Contracts
! Expansions within Existing Contracts
Billings: Catasys contracts are generally designed to provide cash fees on a monthly basis based on enrolled members. To the extent our contracts may include a
minimum performance guarantee; we reserve a portion of the monthly fees that may be at risk until the performance measurement period is completed.
$%&'()*+,',-)+.)/011'.2)3021'%45)6++,)+7)8,9:9;,')<'=;'1&
26. 26
Growth Underway
! Catasys is currently building out a nationwide system for working with patients
! Healthcare is managed on a state by state basis, and the Company’s customers are launching
with them in certain states as they roll out their service
! Each Catasys client has expanded geographically and across multiple modalities
! Achieving economies of scale as more customers are added
! Allows Catasys to achieve higher margins when more states go live
! Every existing customer has expanded OnTrak into new states, new lines of business
(commercial, Medicare and Medicaid plans), or by expanding coverage to include depression
and anxiety
27. 27
! Signing of contract
! Days to launch:
! 45 days to launch in a previously entered state
! 90 days to launch into a new state
! Clinical integration with the health plan requires little effort from the health
plan after transfer of data
! Enrollment is an iterative process after entering into a new state
! Approximately 12 -15 months after launch to achieve steady state of
20% enrollment
20%
1
Day 1
Day 90
Day 45
Launch
45 – 90 Days
12 Months
from
Launch
State Ramp Up – Commercial Substance Use Disorder
28. 28
Significant Ramp in Outreach Pool of Individuals
Catasys saw a significant increase
in eligible member population as
a result of a customer with
programs in eight states resolving
a previous data extraction issue,
existing customer expansion, and
the launch of a new health plan
in Oklahoma.
0
5000
10000
15000
20000
25000
30000
January February March April May June July August September
2017
Monthly through Q3 2017
Outreach totals
increased to 25,000
individuals during the
quarter, which is the
highest in Catasys’
history
Enrollment has
increased by 40% from
the end of the second
quarter.
# of Individuals
29. ! Expanding into new states under existing agreements with health plans
! Expanded focus from high cost SUD populations into other behavioral health conditions, such as
anxiety disorders and depression
! Plan to have agreements with 7 of top 8 health plans in the U.S. by 2018
! Currently have agreements with:
! Potential to adjust criteria for enrollment to lower cost populations (OnTrak-light)
! Target new patient populations, including significant chronic disease members with high
impactable medical costs
!?
Scaling the Business in 2017 / Harvesting Growth in 2018
30. ! Enrollment Increases 40% From Q2 2017 to Present
! OnTrak is currently in Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky, Louisiana,
Massachusetts, Missouri, New Jersey, North Carolina, Oklahoma, Pennsylvania, South Carolina,
Tennessee, Texas, Virginia, West Virginia and Wisconsin
@"
Scaling the Business
!"#$%&'($)*$%+',-'
./$$0"123',"'45'
6,770$0"1'-1%10-
31. 31
RICHARD ANDERSON, President & Chief Operating Officer
! One of main primary architects of the Catasys program, managing strategic development and day-
to-day operations
! Over 15 years of healthcare experience and background in management, finance and mergers &
acquisitions
! Served as Director and Founding Member of Catasys since July 2003 and an officer since April 2005
! Previously a Director and Founding member of PriceWaterhouseCoopers LLP’s, Los Angeles office
transaction support group
Senior Officers ~ Management Interests Aligned with Shareholders
TERREN PEIZER, Founder, Chairman & Chief Executive Officer
! Founder of several health care and life science companies
! Extensive background in venture capital, investing, mergers and acquisitions, corporate finance
! Held senior executive positions with investment banking firms Goldman Sachs, First Boston and
Drexel Burnham Lambert
! Chairman of Acuitas Group Holdings (personal holding company with 75% Ownership of CATS)
! Chairman of Crede Capital Group, LLC, an industry leading Micro-Cap investment company
! Founder and Chairman of NeurMedix, Inc.
Unprecedented
Performance Based Option Plan
! In November, Catasys declared
that employees granted under the
plan, as well as Board members,
will be given options grants with
an exercise price of $7.50 per
share.
! Chairman and Chief Executive
Officer, Terren Peizer’s option
grant will only vest if the common
stock trades of above a VWAP of
$15 a share for an extended
period.
! President and Chief Operating
Officer, Rick Anderson’s option
grant over the next five years tie
to meeting billings expectations
for 2018 and beyond, and
potentially other metrics through
2022, and will be reviewed
annually.
34. @A
Consolidated Statement of Operations
(unaudited)
(In thousands, except for number of shares) September 30, December 31,
2017 2016
ASSETS
Current assets
Cash and cash equivalents 6,926$ 851$
Receivables, net of allowance for doubtful accounts
of $277 and $0, respectively 709 1,052
Prepaids and other current assets 307 420
Total current assets 7,942 2,323
Long-term assets
Property and equipment, net of accumulated depreciation
of $1,751 and $1,620, respectively 553 410
Deposits and other assets 371 371
Total Assets 8,866$ 3,104$
LIABILITIES AND STOCKHOLDERS' EQUITY/(DEFICIT)
Current liabilities
Accounts payable 806$ 870$
Accrued compensation and benefits 901 2,089
Deferred revenue 3,180 1,525
Other accrued liabilities 579 575
Short term debt, related party, net of discount
$0 and $216, respectively - 9,796
Derivative liability - 8,122
Total current liabilities 5,466 22,977
Long-term liabilities
Deferred rent and other long-term liabilities 49 117
Capital leases 6 31
Warrant liabilities 41 5,307
Total Liabilities 5,562 28,432
Stockholders' equity/(deficit)
Preferred stock, $0.0001 par value; 50,000,000 shares authorized;
no shares issued and outstanding - -
Common stock, $0.0001 par value; 500,000,000 shares authorized;
15,889,171 and 9,214,743 shares issued and outstanding
at September 30, 2017 and December 31, 2016, respectively 2 1
Additional paid-in-capital 293,945 254,390
Accumulated deficit (290,643) (279,719)
Total Stockholders' Equity/(Deficit) 3,304 (25,328)
Total Liabilities and Stockholders' Equity/(Deficit) 8,866$ 3,104$
Balance Sheet
(In thousands, except per share amounts)
2017 2016 2017 2016
Revenues
Healthcare services revenues 1,195$ 1,336$ 4,682$ 3,287$
Operating expenses
Cost of healthcare services 1,664 1,253 4,361 3,381
General and administrative 2,575 2,195 8,144 6,518
Depreciation and amortization 47 38 131 102
Total operating expenses 4,286 3,486 12,636 10,001
Loss from operations (3,091) (2,150) (7,954) (6,714)
Other income 16 15 44 90
Interest expense (1) (3,215) (3,408) (4,139)
Loss on conversion of note - - (1,356) -
Loss on issuance of common stock - - (145) -
Change in fair value of derivative liability - (3,484) 132 (6,328)
Change in fair value of warrant liability (2) 1,423 1,767 673
Loss from operations before provision for income taxes (3,078) (7,411) (10,920) (16,418)
Provision for income taxes 2 2 4 7
Net Loss (3,080)$ (7,413)$ (10,924)$ (16,425)$
Basic and diluted net loss from operations per share: ($0.19) ($0.81) ($0.84) ($1.79)
Basic weighted number of shares outstanding 15,889 9,174 13,031 9,170
September 30, September 30,
Three Months Ended Nine Months Ended
The financial statements have been retroactively restated to reflect the 1-for-6 reverse-stock split that occurred on April 25, 2017.
35. @>
Reconciliation of Non-GAAP Measures
CATASYS, INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION
(unaudited)
For the Three Months Ended For the Nine Months Ended
September 30, September 30,
(in thousands) 2017 2016 2017 2016
Revenues $ 1,195 $ 1,336 $ 4,682 $ 3,287
Add:
Net Change in Deferred Revenue 812 430 1,655 1,548
Billings, non-GAAP $ 2,007 $ 1,766 $ 6,337 $ 4,835
* Net change in deferred revenue associated with Q3 billings
!
Non-GAAP Financial Measures
The Company makes reference in this press release to billings, non-GAAP financial measures, as supplemental measures to review and assess our operating performance. The presentation of this non-
GAAP financial measure is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with US GAAP. We define billings as the
amount invoiced in a particular period pursuant to existing contracts based on enrolled members. We use billings as measures of operating performance to assist in comparing performance from
period to period on a consistent basis.
We believe that the use of these non-GAAP financial measures facilitates investors’ assessment of our operating performance from period to period and from company to company by backing out
potential differences caused by variations in the applicable performance requirements contained in the relevant contracts, which may be different from other companies in our industry.
Billings are not defined under GAAP and is not presented in accordance with GAAP. These non-GAAP financial measures have limitations as an analytical tool, and when assessing our operating
performance, investors should not consider them in isolation, or as a substitute for revenue prepared in accordance with GAAP. A reconciliation from these non-GAAP financial measures to the GAAP
financial measures is included at the end of this release.